# US 2023/0263779 A1 · Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0263779 A1
- Document ID: US20230263779A1
- Status: Published application
- Kind: A1
- Application number: 17/850,806
- Filed: 2022-06-27
- Published: 2023-08-24
- Earliest claimed: 2015-06-29
- Assignees: Abraxis BioScience, LLC
- Applicants: Abraxis BioScience, LLC
- Inventors: Neil P. DESAI
- Web page: https://patentgrep.com/patent/US20230263779A1

## CPC

- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/5169: {Proteins, e.g. albumin, gelatin}
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 38/15: Depsipeptides; Derivatives thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61P 35/00: Antineoplastic agents
- A61K 2039/555: {characterised by a specific combination antigen/adjuvant}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods and compositions for the treatment of a solid tumor by administering compositions comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug, e.g., sirolimus or a derivative thereof) and an albumin in combination with compositions comprising a second therapeutic agent.

## Claims

### Claim at position 1

1: A method of treating a solid tumor in an individual, comprising administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin, and b) an effective amount of a second therapeutic agent, wherein the second therapeutic agent is selected from the group consisting of an immunomodulator, a histone deacetylase inhibitor, and a kinase inhibitor.

### Claim at position 2 (depends on 1)

2: The method of claim 1, wherein the solid tumor is bladder cancer, renal cell carcinoma, soft-tissue sarcoma, or melanoma.

### Claim at position 3 (depends on 1)

3: The method of claim 1, wherein the solid tumor is relapsed or refractory to a standard therapy for the solid tumor.

### Claim at position 4 (depends on 1)

4: The method of claim 1, wherein the amount of the mTOR inhibitor in the mTOR inhibitor nanoparticle composition is from about 10 mg/m2 to about 150 mg/m2.

### Claim at position 5

5-6. (canceled)

### Claim at position 6 (depends on 1)

7: The method of claim 1, wherein the mTOR inhibitor nanoparticle composition is administered weekly.

### Claim 8

(canceled)

### Claim at position 8 (depends on 1)

9: The method of claim 1, wherein the mTOR inhibitor nanoparticle composition and the second therapeutic agent are administered sequentially to the individual.

### Claim at position 9 (depends on 1)

10: The method of claim 1, wherein the mTOR inhibitor nanoparticle composition and the second therapeutic agent are administered simultaneously to the individual.

### Claim at position 10 (depends on 1)

11: The method of claim 1, wherein the mTOR inhibitor is a limus drug.

### Claim at position 11 (depends on 11)

12: The method of claim 11, wherein the limus drug is sirolimus.

### Claim at position 12 (depends on 1)

13: The method of claim 1, wherein the average diameter of the nanoparticles in the composition is no greater than about 150 nm.

### Claim 14

(canceled)

### Claim at position 14 (depends on 1)

15: The method of claim 1, wherein the weight ratio of the albumin to the mTOR inhibitor in the nanoparticle composition is no greater than about 9:1.

### Claim at position 15 (depends on 1)

16: The method of claim 1, wherein the nanoparticles comprise the mTOR inhibitor associated with the albumin.

### Claim at position 16

17-18. (canceled)

### Claim at position 17 (depends on 1)

19: The method of claim 1, wherein the mTOR inhibitor nanoparticle composition is administered intravenously.

### Claim at position 18 (depends on 1)

20: The method of claim 1, wherein the individual is human.

### Claim at position 19 (depends on 1)

21: The method of claim 1, further comprising selecting the individual for treatment based on the presence of at least one mTOR-activating aberration.

### Claim at position 20

22-23. (canceled)

### Claim at position 21 (depends on 1)

24: The method of claim 1, wherein the second therapeutic agent is an immunomodulator.

### Claim 25

(canceled)

### Claim at position 23 (depends on 24)

26: The method of claim 24, wherein the immunomodulator is an immune checkpoint inhibitor or an anti-PD-1 antibody.

### Claim at position 24

27-29. (canceled)

### Claim at position 25 (depends on 1)

30: The method of claim 1, wherein the second therapeutic agent is a histone deacetylase inhibitor.

### Claim at position 26

31-33. (canceled)

### Claim at position 27 (depends on 1)

34: The method of claim 1, wherein the second therapeutic agent is a kinase inhibitor.

### Claim at position 28 (depends on 34)

35: The method of claim 34, wherein the kinase inhibitor is a tyrosine kinase inhibitor.

### Claim at position 29

36-44. (canceled)
